NASDAQ · SLS
SELLAS Life Sciences Group, Inc.
$10.16-$0.23 (-2.17%)
SELLAS Life Sciences Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.05% below the high.
Loading market information…
NASDAQ · HRTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Heron Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.37% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Heron Therapeutics, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Heron Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 6, 2025 | $0.01+200.0% vs estimate | $38.90M+1.71% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | $0.02+166.67% vs estimate | $40.78M+11.2% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.03-9.09% vs estimate | $42.27M+13.12% vs estimate |
|---|
THE ANALYST VIEW
19 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.16-$0.23 (-2.17%)
SELLAS Life Sciences Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.05% below the high.
$5.23-$0.05 (-0.95%)
OmniAb, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.68% below the high.
€11.40-€0.06 (-0.52%)
Genfit S.A.’s quoted price sits in the upper half of its reported 52-week range, 26.36% below the high.
$7.25-$0.13 (-1.76%)
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.21% below the high.
$2.61+$0.03 (+0.97%)
Protalix BioTherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.18% below the high.
$13.86+$0.30 (+2.21%)
MediWound Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.64% below the high.
$0.60-$0.01 (-2.37%)
Invivyd, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.39% below the high.
$2.52+$0.03 (+1.2%)
Protara Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.77% below the high.
